COTI-2, a P53 Dependent Treatment for Many Common Cancers, Receives Additional U.S. Patent Protection

Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT),
the bioinformatics and accelerated drug discovery company, is pleased to
announce that the United States ("U.S.") Patent and Trademark Office has
recently granted an additional patent for the Company's lead oncology asset,
COTI-2. COTI-2 now has five U.S. patents granted, with several more pending. 


"We are convinced that it is only a matter of time until the world recognizes
the potential impact of COTI-2 on the treatment of many cancers," said Dr. Wayne
Danter, President and CEO of COTI. "This additional patent provides further
protection and added value to our lead oncology asset. We continue to execute a
prudent strategy for creating long-term, comprehensive intellectual property
coverage for COTI-2 as well as the other compounds in our robust pipeline."


Newly issued patent 

U.S. Patent 8,580,792 covers synergistic combinations of COTI-2 and other
anti-cancer agents in the treatment of cancers that have a RAS mutation, an EGFR
mutation, or that over express AKT2. This covers many cancers that are
notoriously difficult to treat, including colorectal cancers, in which
approximately 50% of the patients do not respond to conventional treatment due
to the presence of a KRAS mutation. The issuance of this latest patent
re-affirms the unique mechanism of action of COTI-2, which based on preclinical
results, provides real potential in treating cancers for which no effective
therapy is currently available, especially when used in combination with other
anti-cancer drugs acting through complementary mechanisms. This latest patent
extends the period of market exclusivity available to COTI and its licensees for
these important pharmaceutical compositions. 


Preclinical development of COTI-2 is ongoing and the Company expects to initiate
clinical evaluation by mid-2014. The Company remains open to, and is actively
seeking, a potential partner for the clinical development of COTI-2.


About Critical Outcome Technologies Inc. 

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective. 


Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024